Expert Rev Neurother. 2008 Mar;8(3):433-55.

Treating multiple sclerosis with monoclonal antibodies.

Source

Julius-Maximilians University, Department of Neurology, Josef-Schneider-Str. 11, 97080 Würzburg, Germany. m.buttmann@uni-wuerzburg.de

Abstract

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three other mAbs (alemtuzumab, rituximab and daclizumab) were successfully tested in Phase II MS trials. In this review, introductory notes on the development and systematic nomenclature of therapeutic mAbs in general, set the stage for a detailed discussion of the four mAbs mentioned. We summarize non-MS indications, expression and function of target antigens, scientific rationales for MS therapy, putative modes of action and pharmacological aspects. Particularly, we provide a critical discussion of clinical MS trials, including protocols and interim analyses of trials currently underway. The natalizumab section pays special attention to the clinical handling of safety issues and the diagnostic use of neutralizing antibodies. We finally develop a scenario for how each of the four mAbs might evolve into the market of MS therapeutics within the coming years.

PMID:: 18345973; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Multiple Sclerosis - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Monoclonal antibody treatments for multiple sclerosis. [Curr Neurol Neurosci Rep. 2008]
Review Monoclonal antibody treatments for multiple sclerosis.
Rose JW, Foley J, Carlson N. Curr Neurol Neurosci Rep. 2008 Sep; 8(5):419-26.
Review Monoclonal antibodies in the therapy of multiple sclerosis: an overview. [J Neurol. 2008]
Review Monoclonal antibodies in the therapy of multiple sclerosis: an overview.
Rommer PS, Stüve O, Goertsches R, Mix E, Zettl UK. J Neurol. 2008 Dec; 255 Suppl 6:28-35.
Review [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]. [Nervenarzt. 2009]
Review [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
Warnke C, Kieseier BC, Zettl U, Hartung HP. Nervenarzt. 2009 Apr; 80(4):468-74.
Review Monoclonal antibodies in the treatment of multiple sclerosis. [Curr Med Chem. 2009]
Review Monoclonal antibodies in the treatment of multiple sclerosis.
Di Pauli F, Berger T, Reindl M. Curr Med Chem. 2009; 16(36):4858-68.
Review Treating multiple sclerosis with monoclonal antibodies: a 2010 update. [Expert Rev Neurother. 2010]
Review Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
Buttmann M. Expert Rev Neurother. 2010 May; 10(5):791-809.

See reviews... See all...

Cited by 4 PubMed Central articles

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. [Ther Adv Neurol Disord. 2009]
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Rojas MA, Carlson NG, Miller TL, Rose JW. Ther Adv Neurol Disord. 2009 Sep; 2(5):291-7.
Escalating immunotherapy of multiple sclerosis. [Ther Adv Neurol Disord. 2008]
Escalating immunotherapy of multiple sclerosis.
Rieckmann P, Traboulsee A, Devonshire V, Oger J. Ther Adv Neurol Disord. 2008 Nov; 1(3):181-92.
Review Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. [MAbs. 2010]
Review Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.
Fontoura P. MAbs. 2010 Nov-Dec; 2(6):670-81.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treating multiple sclerosis with monoclonal antibodies.
Treating multiple sclerosis with monoclonal antibodies.
Expert Rev Neurother. 2008 Mar ;8(3):433-55.

PubMed
In vivo ultrasonic attenuation slope estimates for detecting cervical ripening i...
In vivo ultrasonic attenuation slope estimates for detecting cervical ripening in rats: Preliminary results.
J Acoust Soc Am. 2008 Mar ;123(3):1794-800.

PubMed
Mesoscopic Monte Carlo simulations of stochastic encounters between photoactivat...
Mesoscopic Monte Carlo simulations of stochastic encounters between photoactivated rhodopsin and transducin in disc membranes.
J Phys Chem B. 2008 Apr 10 ;112(14):4419-26. Epub 2008 Mar 18 .

PubMed
Access to health insurance. Year end issue brief.
Access to health insurance. Year end issue brief.
Issue Brief Health Policy Track Serv. 2008 Jan 7 :1-33.

PubMed
Confirmation of biological effects of high dilutions. Effects of submolecular co...
Confirmation of biological effects of high dilutions. Effects of submolecular concentrations of histamine and 1-, 3- and 4-methylhistamines on human basophil activation.
Inflamm Res. 2008 ;57 Suppl 1:S27-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: